AA
CORT icon

ALPS Advisors’s Corcept Therapeutics CORT Stock Holding History

ALPS Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-6,283
Closed -$461K – 1049
2025
Q2 		$461K Buy
6,283
+76
+1% +$5.51K ﹤0.01% 660
2025
Q1 		$709K Sell
6,207
-3,071
-33% -$187K ﹤0.01% 546
2024
Q4 		$468K Sell
9,278
-79,711
-90% -$4.18M ﹤0.01% 625
2024
Q3 		$4.12M Sell
88,989
-6,777
-7% -$241K 0.03% 253
2024
Q2 		$3.11M Buy
95,766
+8,122
+9% +$222K 0.02% 280
2024
Q1 		$2.21M Buy
87,644
+15,284
+21% +$361K 0.02% 333
2023
Q4 		$2.35M Sell
72,360
-3,345
-4% -$91.8K 0.02% 311
2023
Q3 		$2.06M Buy
75,705
+1,041
+1% +$30.1K 0.02% 318
2023
Q2 		$1.66M Buy
74,664
+3,576
+5% +$82.3K 0.01% 346
2023
Q1 		$1.54M Sell
71,088
-1,886
-3% -$41.3K 0.01% 356
2022
Q4 		$1.48M Buy
+72,974
New +$1.83M 0.01% 360
2022
Q3 		– Sell
-14,486
Closed -$344K – 1090
2022
Q2 		$344K Sell
14,486
-149
-1% -$3.25K ﹤0.01% 705
2022
Q1 		$330K Buy
+14,635
New +$311K ﹤0.01% 721
2021
Q1 		– Sell
-14,659
Closed -$383K – 886
2020
Q4 		$383K Sell
14,659
-299
-2% -$6.3K ﹤0.01% 559
2020
Q3 		$260K Buy
+14,958
New +$238K ﹤0.01% 709
2020
Q1 		– Sell
-25,433
Closed -$308K – 816
2019
Q4 		$308K Sell
25,433
-1,127
-4% -$15.7K ﹤0.01% 795
2019
Q3 		$375K Sell
26,560
-4,037
-13% -$49.6K ﹤0.01% 526
2019
Q2 		$341K Sell
30,597
-1,614
-5% -$18K ﹤0.01% 808
2019
Q1 		$378K Sell
32,211
-230
-0.7% -$2.86K ﹤0.01% 809
2018
Q4 		$433K Sell
32,441
-1,308
-4% -$17.3K ﹤0.01% 534
2018
Q3 		$473K Buy
33,749
+8,139
+32% +$114K ﹤0.01% 742
2018
Q2 		$403K Sell
25,610
-1,204
-4% -$20.9K ﹤0.01% 765
2018
Q1 		$441K Buy
26,814
+602
+2% +$11.2K ﹤0.01% 748
2017
Q4 		$473K Hold
26,212
– – ﹤0.01% 602
2017
Q3 		$506K Buy
+26,212
New +$391K ﹤0.01% 490

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

ALPS Advisors's CORT Position: Q3 2025 in Review

ALPS Advisors sold out of Corcept Therapeutics (CORT) in Q3 2025, closing a stake of 6,283 shares — an estimated $461K sold.

ALPS Advisors first reported a position in CORT in Q3 2017 and held it in 25 quarters. The position peaked at $4.12M in Q3 2024. 429 funds tracked by Wall St. Rank hold CORT as of Q3 2025.

  • ALPS Advisors reported no remaining Corcept Therapeutics position as of Q3 2025 after selling out during the quarter.
  • ALPS Advisors sold 6,283 Corcept Therapeutics shares in Q3 2025, an estimated $461K.
  • ALPS Advisors first reported a position in Corcept Therapeutics in Q3 2017 and held it in 25 quarters.
  • ALPS Advisors's Corcept Therapeutics position peaked at $4.12M in Q3 2024.
  • 429 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2025.

Based on ALPS Advisors's 13F filing for Q3 2025, filed 5 Nov 2025.